Related Experiment Video

Updated: Jul 2, 2026

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
14:10

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Targeting blood vessels for the treatment of non-small cell lung cancer

Ethan Amir1, Sarah Hughes, Fiona Blackhall

  • 1Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.

Current Cancer Drug Targets
|August 12, 2008
PubMed

Insights

New antivascular therapies targeting tumor blood vessels offer improved survival for non-small cell lung cancer (NSCLC) patients. This review details these targeted treatments, their efficacy, and future directions in NSCLC therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
  • Current treatments like surgery, radiotherapy, and chemotherapy have reached an efficacy plateau.
  • Novel therapeutic strategies are essential for improving patient survival in NSCLC.

Purpose of the Study:

  • To review the clinical properties and evidence supporting antivascular therapies in NSCLC treatment.
  • To discuss the pitfalls and future directions of these targeted approaches.
  • To explore the molecular mechanisms and biomarkers for antivascular agents in NSCLC.

Main Methods:

  • Literature review of clinical trials and studies on antivascular agents in NSCLC.
  • Analysis of data on targeted therapies, including bevacizumab, vascular disrupting agents (VDAs), and tyrosine kinase inhibitors.
  • Discussion of clinical properties, efficacy, safety, and future research avenues.

Main Results:

  • Bevacizumab, an anti-VEGF antibody, is the first targeted drug demonstrating survival benefit in NSCLC when combined with chemotherapy.
  • Other antivascular agents like VDAs and small-molecule inhibitors show promise in early-phase trials.
  • Antivascular strategies represent a significant advancement in NSCLC treatment.

Conclusions:

  • Antivascular therapies hold significant potential for improving outcomes in NSCLC.
  • Further research is needed to clarify molecular mechanisms and identify predictive biomarkers.
  • Optimizing antivascular strategies is crucial for advancing NSCLC patient care.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...